Tag: sclerosis-drugs
-
U.S. drugmaker Biogen’s profit beats Street; CEO to leave
(Reuters) – Biogen Inc's quarterly adjusted profit blew past Wall Street estimates on higher sales of its multiple sclerosis drugs, and the company said Chief Executive George Scangos would leave in the coming months. Shares of the company, whose board also authorized a $5 billion share repurchase program, rose about 5 percent to $276 in…
-
Theranos hires executives to lead regulatory and compliance push
(Reuters) – Theranos Inc hired two executives to oversee regulatory, quality and compliance standards, in a bid to turn around the struggling blood-testing company after it received sanctions from U.S. regulators.
-
Roche beats forecasts on new drugs and one-off gain
By Ludwig Burger BASEL, Switzerland (Reuters) – Switzerland's Roche beat market expectations for adjusted net income in the first six months of the year, helped by cancer drug sales but also inflated by a one-off gain from its pensions scheme. Core earnings per share, adjusted for certain items, rose 7 percent to 7.74 Swiss francs…